Cerebral metastasis in breast cancer

Abstract

The incidence of breast cancer brain metastases has risen steadily in recent years. Brain metastases are often the limiting factor of the disease, as survival is usually only a few months after brain metastasis occurs. Apart from the poor prognosis, cognitive and neurological deficits lead to a massive impairment of quality of life. HER2-positive or triple-negative cancers develop brain metastases more often. Studies on the subject of brain metastases were conducted mainly in cohorts with different primary tumours. To improve the available data on patients with breast cancer, the “Brain Metastases in Breast Cancer (BMBC)” registry was initiated to record the German care reality. Because of the lack of specific systemic treatment options, the main primary therapy of brain metastases is local (surgery, stereotactic radiation, whole-brain radiation). Local therapy is supplemented by systemic therapy. The choice of systemic therapy is guided especially by the extracranial disease situation, as there are practically no study data currently on the subject of systemic therapy of brain metastases specifically. Only very recently have drugs been investigated explicitly in women with breast cancer brain metastases.

Key words

breast cancer - brain metastasis - radiotherapy - systemic therapy

Schlüsselworter

Mammakarzinom - Hirnmetastasen - Strahlentherapie - systemische Therapie

• References

• 1 Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-1437 . doi:10.1038/nm.3394
• 2 Soni A, Ren Z, Hameed O. et al. Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol 2015; 143: 471-478 . doi:10.1309/ajcpyo5fsv3upexs
• 3 Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013; 23: 573-581 . doi:10.1016/j.ccr.2013.04.017
• 4 Pedrosa R, Mustafa DA, Soffietti R. et al. Breast cancer brain metastasis: molecular mechanisms and directions for treatment. Neuro Oncol 2018; DOI: 10.1093/neuonc/noy044.
• 5 Zhang C, Yu D. Microenvironment determinants of brain metastasis. Cell Biosci 2011; 1: 8 . doi:10.1186/2045-3701-1-8
• 6 Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967; 34: 207-217
• 7 Witzel I, Oliveira-Ferrer L, Pantel K. et al. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 2016; 18: 8 . doi:10.1186/s13058-015-0665-1
• 8 Arvold ND, Oh KS, Niemierko A. et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 2012; 136: 153-160 . doi:10.1007/s10549-012-2243-x
• 9 Laakmann E, Witzel I, Fasching PA. et al. Hirnmetastasierung bei Patientinnen mit Mammakarzinom nach einer neoadjuvanten Chemotherapie. Senologie – Zeitschrift für Mammadiagnostik und -therapie 2018; 15 (02) e30 . doi: 10.1055/s-0038-1651754
• 10 Witzel I, Kantelhardt EJ, Milde-Langosch K. et al. Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer. Onkologie 2011; 34: 304-308 . doi:10.1159/000328679
• 11 Yau T, Swanton C, Chua S. et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006; 45: 196-201 . doi:10.1080/02841860500486630
• 12 Laakmann E, Witzel I, Scriba V. et al. Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry. Int J Mol Sci 2016; 17 DOI: 10.3390/ijms17101615.
• 13 Morikawa A, Jordan L, Rozner R. et al. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. Clin Breast Cancer 2017; 17: 23-28 . doi:10.1016/j.clbc.2016.07.002
• 14 Niikura N, Hayashi N, Masuda N. et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat 2014; 147: 103-112 . doi:10.1007/s10549-014-3090-8
• 15 Thill M, Liedtke C, Müller V. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018. Breast Care 2018; 13: 209-215 . doi: 10.1159/000489331
• 16 Harbeck N, Luftner D, Marschner N. et al. ABC4 Consensus: Assessment by a German Group of Experts. Breast Care (Basel) 2018; 13: 48-58 . doi:10.1159/000486722
• 17 Witzel I. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. European Journal of Cancer 2018; 102: 1-9
• 18 Brown PD, Ballman KV, Cerhan JH. et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18: 1049-1060 . doi:10.1016/s1470-2045(17)30441-2
• 19 Kocher M, Soffietti R, Abacioglu U. et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29: 134-141 . doi:10.1200/JCO.2010.30.1655
• 20 Brown PD, Jaeckle K, Ballman KV. et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. Jama 2016; 316: 401-409 . doi:10.1001/jama.2016.9839
• 21 Stemmler HJ, Mengele K, Schmitt M. et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 2008; 19: 832-836
• 22 Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2010; 21: 942-948 . doi:10.1093/annonc/mdp407
• 23 Swain SM, Baselga J, Miles D. et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol 2014; 25: 1116-1121 . doi:10.1093/annonc/mdu133
• 24 Krop IE, Lin NU, Blackwell K. et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 2015; 26: 113-119 . doi:10.1093/annonc/mdu486
• 25 Bartsch R, Berghoff AS, Vogl U. et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis 2015; 32: 729-737 . doi:10.1007/s10585-015-9740-3
• 26 Borges VF, Ferrario C, Aucoin N. et al. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2 / HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial. JAMA oncology 2018; DOI: 10.1001/jamaoncol.2018.1812.
• 27 Cortes J, Rugo HS, Awada A. et al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat 2017; 165: 329-341 . doi:10.1007/s10549-017-4304-7
• 28 Yamamoto D, Iwase S, Tsubota Y. et al. Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial. OncoTargets and therapy 2012; 5: 185-189 . doi:10.2147/ott.s36515
• 29 Lu YS, Chen TW, Lin CH. et al. Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. Clin Cancer Res 2015; DOI: 10.1158/1078-0432.ccr-14-2075.
• 30 Chen BB, Lu YS, Lin CH. et al. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer 2016; 16: 466 . doi:10.1186/s12885-016-2494-8
• 31 Sara MTolaney NUL, Donald Thornton, Suzanne Klise. et al. Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer. ASCO 2017 (abs 1019)